Annex
United Kingdom
Rejected health claims
| Application – Relevant provisions of Regulation (EC) No 1924/2006 | Nutrient, substance, food or food category | Claim | EFSA opinion reference |
|---|---|---|---|
| Article 14(1)(a) health claim referring to a reduction of a disease risk | ProteQuine® | ProteQuine® elevates/maintains the level of ScIgA on mucous membranes. Decreased or insufficient level of ScIgA is a risk factor in the development of common cold or influenza | Q-2008-397 |
| Article 14(1)(a) health claim referring to a reduction of a disease risk | ProteQuine® in combination with bovine lactoferrin | ProteQuine® in combination with bovine lactoferrin elevates/maintains the level of ScIgA on mucous membranes. Decreased or insufficient level of ScIgA is a risk factor in the development of common cold with sore throat and combination of ProteQuine® with bovine lactoferrin reduces the risk of the development of sore throat | Q-2008-398 |
| Article 14(1)(b) health claim referring to children's development and health | Lactobacillus delbrueckii subsp. bulgaricus strain AY/CSL (LMG P-17224) and Streptococcus thermophilus strain 9Y/CSL (LMG P-17225) | Maintaining the gut health by normalizing the intestinal flora | Q-2008-273 |
| Article 14(1)(b) health claim referring to children's development and health | Beta palmitate | Beta palmitate enrichment contributes to increase calcium absorption | Q-2008-172 |